Grifols, S.A. is a global healthcare company based in Barcelona, Spain, specializing in the development, manufacturing, and distribution of plasma-derived biological medicines. The company operates primarily in three segments: Bioscience, Hospital, and Diagnostic. The Bioscience segment focuses on the research, development, and commercialization of plasma derivatives, which are essential for treating various medical conditions such as hemophilia and immune deficiencies. The Hospital segment offers a range of products for hospital use, including parenteral solutions and nutritional fluids. The Diagnostic segment develops and markets in vitro diagnostic products for clinical laboratories and blood banks. Grifols has significantly expanded its portfolio through acquisitions, notably the purchase of Talecris in 2011 and Biotest in 2022, enhancing its position in the biopharmaceutical market. The company provides its products and services to healthcare providers, hospitals, and distributors globally, underlining its commitment to improving patient care. Founded in 1940, Grifols continues to innovate and collaborate with various health authorities and organizations to advance healthcare solutions.
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.
Alkahest, Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing therapies derived from blood to address neurological diseases, particularly those related to aging, such as Alzheimer’s disease and Parkinson’s disease. Founded in 2014, the company emphasizes research into the beneficial factors found in the blood plasma of younger organisms, which have shown potential in reversing cognitive deficits associated with aging and neurodegenerative conditions in preclinical models. Alkahest operates as a subsidiary of Grifols, S.A., a global healthcare company that specializes in plasma therapies, and strives to enhance health and vitality through innovative treatments aimed at counteracting the effects of aging.
MedKeeper develops mobile and web-based software applications that enhance efficiency and compliance in hospital pharmacy operations. Their suite of secure, hosted applications is utilized by numerous hospitals and medical centers to facilitate communication, ensure compliance, and boost productivity within pharmacy settings. The software provides features such as real-time reporting and analytics, workflow management, inspections, medication tracking, and quality assurance. By leveraging technology, MedKeeper enables healthcare institutions to improve their operational processes and maintain high standards of service in pharmacy management.
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.
Hologic - NAT donor screening unit
Acquisition in 2017
Hologic - NAT donor screening unit engages in research, development and manufacture of assays and instruments based on NAT (Nucleic Acid Testing) technology for transfusion and transplantation screening
Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California
Alkahest, Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing therapies derived from blood to address neurological diseases, particularly those related to aging, such as Alzheimer’s disease and Parkinson’s disease. Founded in 2014, the company emphasizes research into the beneficial factors found in the blood plasma of younger organisms, which have shown potential in reversing cognitive deficits associated with aging and neurodegenerative conditions in preclinical models. Alkahest operates as a subsidiary of Grifols, S.A., a global healthcare company that specializes in plasma therapies, and strives to enhance health and vitality through innovative treatments aimed at counteracting the effects of aging.
Kiro Robotics is a technology company that specializes in the automation of machinery for the hospital sector. It concentrates on developing machines and equipment to automate and control key points of hospital processes, and hospital pharmacy processes in particular, improving the safety of patients and health professionals alike, and delivering increased efficiency.
Celyad Oncology is a clinical-stage biopharmaceutical company based in Mont-Saint-Guibert, Belgium, specializing in the development of CAR-T cell therapies for cancer treatment. The company’s primary product candidates include CYAD-01 and CYAD-02, both autologous cell therapies currently undergoing Phase I clinical trials for relapsed/refractory acute myeloid leukemia. Celyad is also advancing CYAD-101, an allogeneic cell therapy in Phase I trials for metastatic colorectal cancer, and CYAD-103, which is in preclinical development for solid tumors. Other preclinical candidates include CYAD-211 for multiple myeloma, CYAD-221 for B-cell malignancies, and CYAD-231, a dual-specific CAR-T targeting NKG2D and an undisclosed membrane protein. Celyad has established licensing agreements with Novartis regarding allogeneic CAR-T cells and collaborations with Horizon Discovery Group for technology development. The company was founded in 2004 and has previously operated under the name Cardio3 BioSciences.
Progenika Inc. develops and markets diagnostic and prognostic products for the treatment of genetically complex diseases. The company offers diagnostic tests for hypercholesterolemia and fibromyalgia. Additionally, it provides genetic background assessment and blood group phenotypes determination solutions. The company markets its products under the LIPOchip brand name. The company was founded in 2007 and is based in Cambridge, Massachusetts. Progenika Inc. operates as a subsidiary of Progenika Biopharma, S.A.
Araclon Biotech is a biotechnology company focused on the research and development of diagnostic methods and therapies for degenerative diseases, particularly Alzheimer's disease. The company specializes in creating tests for analyzing β-amyloid peptides in human plasma, which are crucial for the early diagnosis of the disease. In addition to diagnostic tools, Araclon Biotech is also engaged in developing immunotherapy vaccines aimed at targeting β-amyloid peptides, thereby helping to prevent or delay the onset of Alzheimer's symptoms. The company is involved in the scientific investigation, creation, and commercialization of pharmacological and biotechnological products, utilizing both its own and external patents in the field.
Talecris Biotherapeutics is a biopharmaceutical company that produces and markets plasma-derived protein therapies. Talecris Biotherapeutics was founded in 2004 and is based in Barcelona, Spain.
Celyad Oncology is a clinical-stage biopharmaceutical company based in Mont-Saint-Guibert, Belgium, specializing in the development of CAR-T cell therapies for cancer treatment. The company’s primary product candidates include CYAD-01 and CYAD-02, both autologous cell therapies currently undergoing Phase I clinical trials for relapsed/refractory acute myeloid leukemia. Celyad is also advancing CYAD-101, an allogeneic cell therapy in Phase I trials for metastatic colorectal cancer, and CYAD-103, which is in preclinical development for solid tumors. Other preclinical candidates include CYAD-211 for multiple myeloma, CYAD-221 for B-cell malignancies, and CYAD-231, a dual-specific CAR-T targeting NKG2D and an undisclosed membrane protein. Celyad has established licensing agreements with Novartis regarding allogeneic CAR-T cells and collaborations with Horizon Discovery Group for technology development. The company was founded in 2004 and has previously operated under the name Cardio3 BioSciences.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.